Abstract
Recent progress in biomarker research, neuromethods development, and clinical practice has contributed to advances in stroke diagnoses and treatment optimization. At present, no “perfect” biomarker(s) exists for stroke. A “perfect” biomarker could assist in risk assessment, predict and distinguish the stroke from mimicking conditions, and measure disease progression. Neurofunctional biomarkers, structural imaging biomarkers, and molecular biologic markers all have the potential to revolutionize the screening, diagnosis, prognosis, and prediction of disease recurrence as well as therapeutic monitoring of stroke and transient ischemic attack (TIA).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
World Health Organization (2001) Biomarkers in risk assessment: validity and validation. http://www.inchem.org/documents/ehc/ehc/ehc222. Accessed 12 Jan 2019
Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89–95. https://doi.org/10.1067/mcp.2001.113989
Dichgans M (2007) Genetics of ischaemic stroke. Lancet Neurol 6(2):149–161. https://doi.org/10.1016/S1474-4422(07)70028-5
Traylor M, Farrall M, Holliday EG, Sudlow C, Hopewell JC, Cheng YC, Fornage M, Ikram MA, Malik R, Bevan S, Thorsteinsdottir U, Nalls MA, Longstreth W, Wiggins KL, Yadav S, Parati EA, Destefano AL, Worrall BB, Kittner SJ, Khan MS, Reiner AP, Helgadottir A, Achterberg S, Fernandez-Cadenas I, Abboud S, Schmidt R, Walters M, Chen WM, Ringelstein EB, O’Donnell M, Ho WK, Pera J, Lemmens R, Norrving B, Higgins P, Benn M, Sale M, Kuhlenbäumer G, Doney AS, Vicente AM, Delavaran H, Algra A, Davies G, Oliveira SA, Palmer CN, Deary I, Schmidt H, Pandolfo M, Montaner J, Carty C, de Bakker PI, Kostulas K, Ferro JM, van Zuydam NR, Valdimarsson E, Nordestgaard BG, Lindgren A, Thijs V, Slowik A, Saleheen D, Paré G, Berger K, Thorleifsson G, Australian Stroke Genetics Collaborative, Wellcome Trust Case Control Consortium 2 (WTCCC2), Hofman A, Mosley TH, Mitchell BD, Furie K, Clarke R, Levi C, Seshadri S, Gschwendtner A, Boncoraglio GB, Sharma P, Bis JC, Gretarsdottir S, Psaty BM, Rothwell PM, Rosand J, Meschia JF, Stefansson K, Dichgans M, Markus HS; International Stroke Genetics Consortium (2012) Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol 11(11):951–962. https://doi.org/10.1016/S1474-4422(12)70234-X
Gomez-Uriz AM, Milagro FI, Mansego ML, Cordero P, Abete I, De Arce A, Goyenechea E, Blázquez V, Martínez-Zabaleta M, Martínez JA, López De Munain A, Campión J (2015) Obesity and ischemic stroke modulate the methylation levels of KCNQ1 in white blood cells. Hum Mol Genet 24(5):1432–1440. https://doi.org/10.1093/hmg/ddu559
Boyd LA, Hayward KS, Ward NS, Stinear CM, Rosso C, Fisher RJ, Carter AR, Leff AP, Copland DA, Carey LM, Cohen LG, Basso DM, Maguire JM, Cramer SC (2017) Biomarkers of stroke recovery: Consensus-based core recommendations from the stroke recovery and rehabilitation roundtable. Neurorehabil Neural Repair 31(10–11):864–876. https://doi.org/10.1177/1545968317732680
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Peplow, P.V., Martinez, B., Dambinova, S.A. (2020). Trends in Biomarkers Development for Stroke. In: Peplow, P.V., Martinez, B., Dambinova, S.A. (eds) Stroke Biomarkers. Neuromethods, vol 147. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9682-7_20
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9682-7_20
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9681-0
Online ISBN: 978-1-4939-9682-7
eBook Packages: Springer Protocols